Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Going beyond Polycomb: EZH2 functions in prostate cancer
Su H. Park, Ka-wing Fong, Ezinne F. Mong, et al.
Oncogene (2021) Vol. 40, Iss. 39, pp. 5788-5798
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Jing Yang, Jin Xu, Wei Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 143
Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future
Dilara Akhoundova, Mark A. Rubin
Cancer Cell (2022) Vol. 40, Iss. 9, pp. 920-938
Open Access | Times Cited: 92
Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer
Lourdes Brea, Jindan Yu
Trends in Endocrinology and Metabolism (2025)
Closed Access | Times Cited: 3
3D chromatin architecture and transcription regulation in cancer
Siwei Deng, Yuliang Feng, Siim Pauklin
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 47
Calcium signalling pathways in prostate cancer initiation and progression
Roberto Silvestri, Vanessa Nicolì, Priyadarsini Gangadharannambiar, et al.
Nature Reviews Urology (2023) Vol. 20, Iss. 9, pp. 524-543
Closed Access | Times Cited: 26
Prostate cancer epigenetics — from pathophysiology to clinical application
Vera Constâncio, João Lobo, José Pedro Sequeira, et al.
Nature Reviews Urology (2025)
Closed Access | Times Cited: 1
EZH2 and NF-κB: A context-dependent crosstalk and transcriptional regulation in cancer
Parminder Kaur, Shiv Verma, Prem Prakash Kushwaha, et al.
Cancer Letters (2023) Vol. 560, pp. 216143-216143
Open Access | Times Cited: 17
Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics
Qichao Bao, Anil Kumar, Daqing Wu, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 6, pp. 103986-103986
Open Access | Times Cited: 6
EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies
Ivana Samaržija, Marko Tomljanović, Renata Novak Kujundžić, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4761-4761
Open Access | Times Cited: 23
A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformation
Jun Wang, Kwang‐Su Park, Xufen Yu, et al.
Nucleic Acids Research (2022) Vol. 50, Iss. 19, pp. 10929-10946
Open Access | Times Cited: 23
Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential
R Ragavi, Panneerselvam Muthukumaran, Srividhya Nandagopal, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 41, Iss. 8, pp. 340-353
Closed Access | Times Cited: 13
EZH2‐associated tumor malignancy: A prominent target for cancer treatment
Maryam Sabour Takanlou, Leila Sabour Takanlou, Çiğir Biray-Avci
Clinical Genetics (2024) Vol. 106, Iss. 4, pp. 377-385
Open Access | Times Cited: 5
Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond
Jianwei Feng, Xinyue Meng
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development
Ye Jin, Tianjia Liu, Haoming Luo, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 20
Cancer Stemness/Epithelial–Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target
Enrique A. Castellón, Sebastián Indo, Héctor R. Contreras
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14917-14917
Open Access | Times Cited: 19
The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
Victor M. Matias-Barrios, Xuesen Dong
Pharmaceuticals (2023) Vol. 16, Iss. 1, pp. 94-94
Open Access | Times Cited: 12
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis
Feng Li, Pengqiao Wang, Jun Ye, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
EZH2‐mediated downregulation of miR‐155‐5p contributes to prostate cancer cell malignancy through SMAD2 and TAB2
Zhijie Bai, Jiayi Liu, Wenqun Xing, et al.
The Kaohsiung Journal of Medical Sciences (2025)
Open Access
Cellular Signaling of Amino Acid Metabolism in Prostate Cancer
Ping Yao, Shiqi Cao, Zhiguang Zhu, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 776-776
Open Access
A Bioactive Benzimidazole‐Cyclometalated Iridium(III) Complex as an Epigenetic Regulator through Effectively Interrupting the EED–EZH2 Interaction
Shasha Cheng, Jian‐Dong Li, Yingqi Song, et al.
Small (2025)
Closed Access
Enhancing Curcumol Delivery through PD-1 Targeted Nanocarriers: A Novel Therapeutic Approach for Prostate Cancer
Hao Zhang, Yang Du, Xujia Liu, et al.
Phytomedicine (2025) Vol. 141, pp. 156595-156595
Closed Access
WITHDRAWN: GATA2 promotes castration-resistant prostate cancer development by suppressing IFN-β axis-mediated antitumor immunity
MAFEI XU, Zige Jin, Hanling Wang, et al.
Research Square (Research Square) (2025)
Closed Access
Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer
Yi Yang, Yanqiang Li, Chao Li, et al.
Oncogene (2022) Vol. 41, Iss. 11, pp. 1610-1621
Open Access | Times Cited: 16
Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells
Aide Negri, Marina Marozzi, Daniela Trisciuoglio, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top